Ingo A. Eland

1.0k total citations
22 papers, 660 citations indexed

About

Ingo A. Eland is a scholar working on Surgery, Pediatrics, Perinatology and Child Health and Epidemiology. According to data from OpenAlex, Ingo A. Eland has authored 22 papers receiving a total of 660 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 5 papers in Pediatrics, Perinatology and Child Health and 4 papers in Epidemiology. Recurrent topics in Ingo A. Eland's work include Pancreatitis Pathology and Treatment (7 papers), Pharmaceutical studies and practices (4 papers) and Vitamin K Research Studies (3 papers). Ingo A. Eland is often cited by papers focused on Pancreatitis Pathology and Treatment (7 papers), Pharmaceutical studies and practices (4 papers) and Vitamin K Research Studies (3 papers). Ingo A. Eland collaborates with scholars based in Netherlands, United Kingdom and New Zealand. Ingo A. Eland's co-authors include Miriam Sturkenboom, Bruno H. Stricker, Johan van der Lei, B H Stricker, Eugène van Puijenbroek, J. H. P. Wilson, Geert W. ‘t Jong, Consuelo Huerta, Paul van der Linden and John van den Anker and has published in prestigious journals such as Gastroenterology, European Respiratory Journal and The American Journal of Gastroenterology.

In The Last Decade

Ingo A. Eland

22 papers receiving 631 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ingo A. Eland Netherlands 12 296 195 155 107 105 22 660
G Nocea Spain 14 203 0.7× 51 0.3× 47 0.3× 238 2.2× 57 0.5× 42 750
J.J. Kerssens United Kingdom 12 91 0.3× 50 0.3× 94 0.6× 153 1.4× 80 0.8× 32 586
Francisco Ortega Spain 16 151 0.5× 111 0.6× 96 0.6× 38 0.4× 76 0.7× 32 816
Christopher M. Dezii United States 11 153 0.5× 45 0.2× 53 0.3× 272 2.5× 38 0.4× 20 991
M. Kohnle Germany 13 208 0.7× 96 0.5× 153 1.0× 24 0.2× 22 0.2× 22 652
Andrew M. Peterson United States 8 51 0.2× 90 0.5× 82 0.5× 51 0.5× 69 0.7× 14 718
Sanne Rasmussen Denmark 13 220 0.7× 69 0.4× 35 0.2× 29 0.3× 87 0.8× 48 763
Carole Ayav France 14 105 0.4× 50 0.3× 46 0.3× 52 0.5× 73 0.7× 55 660
Theodore Darkow United States 13 96 0.3× 47 0.2× 62 0.4× 66 0.6× 30 0.3× 20 678
Olusegun Famure Canada 14 324 1.1× 117 0.6× 93 0.6× 30 0.3× 30 0.3× 56 814

Countries citing papers authored by Ingo A. Eland

Since Specialization
Citations

This map shows the geographic impact of Ingo A. Eland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingo A. Eland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingo A. Eland more than expected).

Fields of papers citing papers by Ingo A. Eland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingo A. Eland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingo A. Eland. The network helps show where Ingo A. Eland may publish in the future.

Co-authorship network of co-authors of Ingo A. Eland

This figure shows the co-authorship network connecting the top 25 collaborators of Ingo A. Eland. A scholar is included among the top collaborators of Ingo A. Eland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingo A. Eland. Ingo A. Eland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eland, Ingo A., Lars P. Klieverik, Abbas Ali Mansour, & Abdulbaqi Al–Toma. (2022). Gluten-Free Diet in Co-Existent Celiac Disease and Type 1 Diabetes Mellitus: Is It Detrimental or Beneficial to Glycemic Control, Vascular Complications, and Quality of Life?. Nutrients. 15(1). 199–199. 12 indexed citations
2.
Wille, J., et al.. (2014). The value of parathyroid I-123/Tc-99m subtraction SPECT/CT in primary hyperparathyroidism. 55(2). 477–477. 2 indexed citations
3.
Yarde, F., Yvonne T. van der Schouw, Harold W. de Valk, et al.. (2014). Age at menopause in women with type 1 diabetes mellitus: the OVADIA study. Human Reproduction. 30(2). 441–6. 31 indexed citations
4.
Beek, E.S.J. van der, Valerie M. Monpellier, Ingo A. Eland, Ellen Tromp, & Bert van Ramshorst. (2014). Nutritional Deficiencies in Gastric Bypass Patients; Incidence, Time of Occurrence and Implications for Post-operative Surveillance. Obesity Surgery. 25(5). 818–823. 44 indexed citations
5.
Veneman, Thiemo, et al.. (2012). From insulin detemir to glargine: Effect on glycemic control and psychological wellbeing in patients with diabetes mellitus type 2 in daily practice. Journal of Diabetes Mellitus. 2(1). 101–108. 1 indexed citations
7.
Eland, Ingo A., Anders Sundström, Morten Andersen, et al.. (2006). Antihypertensive medication and the risk of acute pancreatitis: The European case-control study on drug-induced acute pancreatitis (EDIP). Scandinavian Journal of Gastroenterology. 41(12). 1484–1490. 49 indexed citations
8.
Jong, Geert W. ‘t, et al.. (2004). Unlicensed and off-label prescription of respiratory drugs to children. European Respiratory Journal. 23(2). 310–313. 40 indexed citations
9.
Jong, Geert W. ‘t, Ingo A. Eland, Miriam Sturkenboom, John N. van den Anker, & Bruno H. Stricker. (2003). Determinants for drug prescribing to children below the minimum licensed age. European Journal of Clinical Pharmacology. 58(10). 701–705. 28 indexed citations
10.
Jong, Geert ‘t, Paul van der Linden, Elisabeth Bakker, et al.. (2002). Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. European Journal of Clinical Pharmacology. 58(4). 293–297. 69 indexed citations
11.
Jong, Geert W. ‘t, Ingo A. Eland, Matthijs de Hoog, et al.. (2002). Unlicensed and Off-label Prescription of Systemic Anti-infective Agents to Children. EUR Research Repository (Erasmus University Rotterdam). 5(2). 68–74. 8 indexed citations
12.
Eland, Ingo A., Johan van der Lei, Bruno H. Stricker, & Miriam Sturkenboom. (2001). Incidence of priapism in the general population. Urology. 57(5). 970–972. 168 indexed citations
13.
Eland, Ingo A., et al.. (2000). The risk of acute pancreatitis associated with acid‐suppressing drugs. British Journal of Clinical Pharmacology. 49(5). 473–478. 44 indexed citations
14.
Eland, Ingo A., Miriam Sturkenboom, Frank C. Bekkering, et al.. (2000). Acute pancreatitis attributed to the use of interferon alfa-2b. Gastroenterology. 119(1). 230–233. 34 indexed citations
15.
Eland, Ingo A., Eugène van Puijenbroek, Miriam Sturkenboom, J. H. P. Wilson, & B H Stricker. (1999). Drug-Associated Acute Pancreatitis: Twenty-One Years of Spontaneous Reporting in The Netherlands. The American Journal of Gastroenterology. 94(9). 2417–2422. 89 indexed citations
16.
Eland, Ingo A., Anton S. M. Dofferhoff, Matthijs Vink, Pieter E. Zondervan, & Bruno H. Stricker. (1999). Colitis May Be Part of the Antiepileptic Drug Hypersensitivity Syndrome. Epilepsia. 40(12). 1780–1783. 25 indexed citations
17.
Eland, Ingo A.. (1999). Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in the Netherlands. The American Journal of Gastroenterology. 94(9). 2417–2422. 5 indexed citations
18.
Eland, Ingo A., et al.. (1998). [Cholestatic hepatitis ascribed to the use of thiabendazole].. PubMed. 142(23). 1331–4. 4 indexed citations
19.
Eland, Ingo A., et al.. (1998). [Provision of taxoids in 1996: inequality of care].. PubMed. 142(10). 518–21. 2 indexed citations
20.
Eland, Ingo A., et al.. (1998). Incidence and mortality of acute pancreatitis in the Netherlands between 1985 and 1995. European Journal of Gastroenterology & Hepatology. 10(12). A87–A87. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026